Rep. David Taylor Purchases Amgen Inc. (NASDAQ:AMGN) Stock

Representative David Taylor (Republican-Ohio) recently bought shares of Amgen Inc. (NASDAQ:AMGN). In a filing disclosed on June 12th, the Representative disclosed that they had bought between $1,001 and $15,000 in Amgen stock on June 5th. The trade occurred in the Representative’s “DAVID TAYLOR TRUST > SARDINIA READY MIX 401(K) – DAVE” account.

Representative David Taylor also recently made the following trade(s):

• Purchased $1,001 – $15,000 in shares of American Electric Power (NASDAQ:AEP) on 6/5/2026.
• Sold $1,001 – $15,000 in shares of Lam Research (NASDAQ:LRCX) on 6/5/2026.
• Purchased $1,001 – $15,000 in shares of Kroger (NYSE:KR) on 6/5/2026.
• Purchased $1,001 – $15,000 in shares of AT&T (NYSE:T) on 6/5/2026.
• Sold $1,001 – $15,000 in shares of Amazon.com (NASDAQ:AMZN) on 6/5/2026.
• Purchased $1,001 – $15,000 in shares of Alphabet (NASDAQ:GOOGL) on 6/5/2026.
• Purchased $1,001 – $15,000 in shares of Medpace (NASDAQ:MEDP) on 5/15/2026.
• Sold $1,001 – $15,000 in shares of Alphabet (NASDAQ:GOOGL) on 5/15/2026.
• Purchased $1,001 – $15,000 in shares of Home Depot (NYSE:HD) on 5/15/2026.
• Purchased $1,001 – $15,000 in shares of AT&T (NYSE:T) on 5/15/2026.

Amgen Stock Performance

Shares of AMGN traded up $6.13 during mid-day trading on Thursday, hitting $357.56. The company’s stock had a trading volume of 341,238 shares, compared to its average volume of 2,777,438. Amgen Inc. has a one year low of $269.77 and a one year high of $391.29. The stock’s 50-day moving average is $340.45 and its two-hundred day moving average is $345.95. The firm has a market capitalization of $192.98 billion, a PE ratio of 24.97, a price-to-earnings-growth ratio of 3.48 and a beta of 0.42. The company has a debt-to-equity ratio of 5.65, a quick ratio of 1.01 and a current ratio of 1.26.

Amgen (NASDAQ:AMGN) last released its earnings results on Thursday, April 30th. The medical research company reported $5.15 EPS for the quarter, beating the consensus estimate of $4.77 by $0.38. Amgen had a net margin of 20.96% and a return on equity of 137.41%. The firm had revenue of $8.62 billion during the quarter, compared to analysts’ expectations of $8.58 billion. During the same period in the prior year, the company earned $4.90 EPS. The business’s quarterly revenue was up 5.8% compared to the same quarter last year. Amgen has set its FY 2026 guidance at 21.700-23.100 EPS. As a group, sell-side analysts anticipate that Amgen Inc. will post 22.38 EPS for the current year.

Insider Buying and Selling

In other Amgen news, SVP Nancy A. Grygiel sold 1,237 shares of the stock in a transaction on Monday, May 4th. The shares were sold at an average price of $323.73, for a total value of $400,454.01. Following the sale, the senior vice president directly owned 7,009 shares in the company, valued at approximately $2,269,023.57. This trade represents a 15.00% decrease in their ownership of the stock. The transaction was disclosed in a document filed with the SEC, which is accessible through the SEC website. Insiders own 0.85% of the company’s stock.

Wall Street Analyst Weigh In

A number of analysts have recently issued reports on the company. Guggenheim lowered their price objective on Amgen from $351.00 to $340.00 and set a “neutral” rating on the stock in a research report on Monday, May 4th. Wells Fargo & Company boosted their price target on shares of Amgen from $375.00 to $390.00 and gave the company an “equal weight” rating in a report on Thursday, March 19th. Wall Street Zen upgraded shares of Amgen from a “hold” rating to a “buy” rating in a research note on Sunday, June 14th. UBS Group raised their price objective on shares of Amgen from $390.00 to $400.00 and gave the stock a “buy” rating in a report on Monday, April 13th. Finally, Truist Financial lifted their target price on shares of Amgen from $325.00 to $327.00 and gave the company a “hold” rating in a research report on Friday, May 1st. Two investment analysts have rated the stock with a Strong Buy rating, eleven have assigned a Buy rating, fifteen have assigned a Hold rating and two have assigned a Sell rating to the stock. According to data from MarketBeat.com, Amgen has a consensus rating of “Hold” and an average price target of $354.42.

Institutional Inflows and Outflows

Institutional investors have recently modified their holdings of the company. Robeco Institutional Asset Management B.V. grew its position in shares of Amgen by 10.0% during the 4th quarter. Robeco Institutional Asset Management B.V. now owns 481,453 shares of the medical research company’s stock worth $157,584,000 after buying an additional 43,884 shares during the period. Curtis Advisory Group LLC acquired a new stake in shares of Amgen in the 4th quarter valued at approximately $1,669,000. Adell Harriman & Carpenter Inc. boosted its stake in Amgen by 7.9% during the 4th quarter. Adell Harriman & Carpenter Inc. now owns 22,008 shares of the medical research company’s stock worth $7,204,000 after acquiring an additional 1,609 shares during the last quarter. Fideuram Intesa Sanpaolo Private Banking S.P.A. bought a new position in Amgen during the 4th quarter worth approximately $22,441,000. Finally, Robinhood Asset Management LLC acquired a new position in Amgen during the fourth quarter valued at approximately $17,526,000. Institutional investors own 76.50% of the company’s stock.

About Representative Taylor

David Taylor (Republican Party) is a member of the U.S. House, representing Ohio’s 2nd Congressional District. He assumed office on January 3, 2025. His current term ends on January 3, 2027.

Taylor (Republican Party) ran for election to the U.S. House to represent Ohio’s 2nd Congressional District. He won in the general election on November 5, 2024.

David Taylor graduated from Amelia High School. Taylor earned degrees from Miami University (Ohio) and the University of Dayton School of Law. Taylor’s career experience includes working as an attorney and as a businessman at Sardinia Ready Mix, Inc.

Amgen Company Profile

Amgen Inc (NASDAQ: AMGN) is a global biotechnology company founded in 1980 and headquartered in Thousand Oaks, California. The company focuses on discovering, developing, manufacturing and delivering human therapeutics that address serious illnesses. Amgen’s work centers on biologic medicines derived from cellular and molecular biology, with an emphasis on translating advances in human genetics and protein science into therapies for patients.

Amgen’s commercial portfolio has historically included biologics used in oncology, supportive care, nephrology, bone health and cardiovascular disease.